![Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study]()
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II studySmyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; Comen, E. A.; Drullinsky, P. R.; Traina, T. A.; Troso-Sandoval, T.; Baselga, J.; Norton, L.; Hudis, C. A.; Dang, C. T. · Breast Cancer Research and Treatment · 2016